Volume and Infusion Rate Dynamics of Intraparenchymal Central Nervous System Infusion in a Large Animal Model
Authors:
- Toloo TaghianTTToloo Taghian
- Erin HornEHErin Horn
- Mohammed Salman ShazeebMSMohammed Salman Shazeeb
- Lindsey J. BierfeldtLBLindsey J. Bierfeldt
- Susan M. TuominenSTSusan M. Tuominen
- Jennifer KoehlerJKJennifer Koehler
- Deborah FernauDFDeborah Fernau
- Stephanie BertrandSBStephanie Bertrand
- Stephen FreySFStephen Frey
- Oguz I. CataltepeOCOguz I. Cataltepe
- Matthew J. GounisMGMatthew J. Gounis
- Aly H. AbayazeedAAAly H. Abayazeed
- 12 June 2020
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 31 (11-12) , 617-625
Abstract
Thalamic infusion of adeno-associated viral (AAV) vectors has been shown to have therapeutic effects in neuronopathic lysosomal storage diseases. Preclinical studies in sheep model of Tay-Sachs disease demonstrated that bilateral thalamic injections of AAV gene therapy are required for maximal benefit. Translation of thalamic injection to patients carries risks in that (1) it has never been done in humans, and (2) dosing scale-up based on brain weight from animals to humans requires injection of larger volumes. To increase the safety margin of this infusion, a flexible cannula was selected to enable simultaneous bilateral thalamic infusion in infants while monitoring by imaging and/or to enable awake infusions for injection of large volumes at low infusion rates. In this study, we tested various infusion volumes (200–800 μL) and rates (0.5–5 μL/min) to determine the maximum tolerated combination of injection parameters. Animals were followed for ∼1 month postinjection with magnetic resonance imaging (MRI) performed at 14 and 28 days. T1-weighted MRI was used to quantify thalamic damage followed by histopathological assessment of the brain. Trends in data show that infusion volumes of 800 μL (2 × the volume required in sheep based on thalamic size) resulted in larger lesions than lower volumes, where the long infusion times (between 13 and 26 h) could have contributed to the generation of larger lesions. The target volume (400 μL, projected to be sufficient to cover most of the sheep thalamus) created the smallest lesion size. Cannula placement alone did result in damage, but this is likely associated with an inherent limitation of its use in a small brain due to the length of the distal rigid portion and lack of stable fixation. An injection rate of 5 μL/min at a volume ∼1/3 of the thalamus (400–600 μL) appears to be well tolerated in sheep both clinically and histopathologically.Keywords
This publication has 31 references indexed in Scilit:
- A Longitudinal Analysis of Regional Brain Volumes in Macaques Exposed to X-Irradiation in Early GestationPLOS ONE, 2012
- Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman PrimatesHuman Gene Therapy, 2012
- Natural History of Infantile GM2 GangliosidosisPediatrics, 2011
- Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric DisordersMolecular Therapy, 2011
- Magnetic Resonance Imaging-Guided Delivery of Adeno-Associated Virus Type 2 to the Primate Brain for the Treatment of Lysosomal Storage DisordersHuman Gene Therapy, 2010
- Efficient gene therapy-based method for the delivery of therapeutics to primate cortexProceedings of the National Academy of Sciences, 2009
- Results from a phase I safety trial of hAADC gene therapy for Parkinson diseaseNeurology, 2008
- Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNAHuman Gene Therapy, 2008
- Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( ASPA ) to the Human BrainHuman Gene Therapy, 2002
- MR Findings in Tay-Sachs DiseaseJournal of Computer Assisted Tomography, 1996